Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
Daniel E. Freedberg, Joseph Conigliaro, Timothy C. Wang, et al.
Gastroenterology (2020) Vol. 159, Iss. 3, pp. 1129-1131.e3
Open Access | Times Cited: 253

Showing 1-25 of 253 citing articles:

COVID-19: Discovery, diagnostics and drug development
Tarik Asselah, David Durantel, Éric Pasmant, et al.
Journal of Hepatology (2020) Vol. 74, Iss. 1, pp. 168-184
Open Access | Times Cited: 413
An aberrant STAT pathway is central to COVID-19
T. Matsuyama, Shawn P. Kubli, Steven K. Yoshinaga, et al.
Cell Death and Differentiation (2020) Vol. 27, Iss. 12, pp. 3209-3225
Open Access | Times Cited: 284
Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome
Lawrence B. Afrin, Leonard B. Weinstock, Gerhard J. Molderings
International Journal of Infectious Diseases (2020) Vol. 100, pp. 327-332
Open Access | Times Cited: 283
Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations
Nicholas G. Kounis, Ioanna Koniari, Cesare de Gregorio, et al.
Vaccines (2021) Vol. 9, Iss. 3, pp. 221-221
Open Access | Times Cited: 186
A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic
Chris R. Triggle, Devendra Bansal, Hong Ding, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 166
Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
Dimple Chakravarty, Sujit S. Nair, Nada Hammouda, et al.
Communications Biology (2020) Vol. 3, Iss. 1
Open Access | Times Cited: 141
Mast cell activation symptoms are prevalent in Long-COVID
Leonard B. Weinstock, Jill Brook, Arthur S. Walters, et al.
International Journal of Infectious Diseases (2021) Vol. 112, pp. 217-226
Open Access | Times Cited: 137
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 129
Combating Oxidative Stress and Inflammation in COVID‐19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives
Duried Alwazeer, Franky Fuh-Ching Liu, Xiao Yu Wu, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 105
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
Tobias Janowitz, Eva Gablenz, David Pattinson, et al.
Gut (2020) Vol. 69, Iss. 9, pp. 1592-1597
Open Access | Times Cited: 136
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
Jeffrey Mather, Richard L. Seip, Raymond G. McKay
The American Journal of Gastroenterology (2020) Vol. 115, Iss. 10, pp. 1617-1623
Open Access | Times Cited: 121
COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
Richard H. Hunt, James E. East, Ángel Lanas, et al.
Digestive Diseases (2020) Vol. 39, Iss. 2, pp. 119-139
Open Access | Times Cited: 121
Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients
Reed B. Hogan, Reed B. Hogan, Tim Cannon, et al.
Pulmonary Pharmacology & Therapeutics (2020) Vol. 63, pp. 101942-101942
Open Access | Times Cited: 107
Identification of antiviral antihistamines for COVID-19 repurposing
Leah R. Reznikov, Michael H. Norris, Rohit Vashisht, et al.
Biochemical and Biophysical Research Communications (2020) Vol. 538, pp. 173-179
Open Access | Times Cited: 104
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action
Hassan Yousefi, Ladan Mashouri, Samuel C. Okpechi, et al.
Biochemical Pharmacology (2020) Vol. 183, pp. 114296-114296
Open Access | Times Cited: 102
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
Robert W. Malone, Philip Tisdall, Philip Fremont‐Smith, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 98
Drug Inhibition of SARS-CoV-2 Replication in Human Pluripotent Stem Cell–Derived Intestinal Organoids
Jana Krüger, Rüdiger Groß, Carina Conzelmann, et al.
Cellular and Molecular Gastroenterology and Hepatology (2020) Vol. 11, Iss. 4, pp. 935-948
Open Access | Times Cited: 96
COVID-19 Therapeutic Options Under Investigation
Malak Kaddoura, Malak Al Ibrahim, Ghina Hijazi, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 83
COVID-19—Lessons Learned and Questions Remaining
Ferric C. Fang, Constance A. Benson, Carlos del Rı́o, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 12, pp. 2225-2240
Open Access | Times Cited: 77
Recent advances in management of COVID-19: A review
Soraya Mouffak, Qamar Shubbar, Ekram Saleh, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112107-112107
Open Access | Times Cited: 76
Nanomedicine as A Promising Approach For Diagnosis, Treatment and Prophylaxis Against COVID-19
Noura H. Abd Ellah, Sheryhan F. Gad, Khalid Muhammad, et al.
Nanomedicine (2020) Vol. 15, Iss. 21, pp. 2085-2102
Open Access | Times Cited: 72
Inhibitors of SARS-CoV-2 PLpro
Dale J. Calleja, Guillaume Lessène, David Komander
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 67
Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – A retrospective observational study in elderly patients
Juan Ignacio Morán Blanco, Judith A. Alvarenga Bonilla, Sakae Homma, et al.
Pulmonary Pharmacology & Therapeutics (2021) Vol. 67, pp. 101989-101989
Open Access | Times Cited: 65
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 62
Responses of Mast Cells to Pathogens: Beneficial and Detrimental Roles
Mariela Jiménez, Daniel Cervantes‐García, Laura Elena Córdova-Dávalos, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 58
Page 1 - Next Page

Scroll to top